AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15825785 — intervention group
Group type: EXPERIMENTAL
Intervention: acetaminophen/acetaminophen
Number of subjects: 150
Study 15825785 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium/naproxen sodium
Number of subjects: 150
Study 15825785 — intervention group
Group type: EXPERIMENTAL
Intervention: aspirin/aspirin
Number of subjects: 150
Study 15825785 — intervention group
Group type: COMPARATOR
Intervention: placebo/placebo
Number of subjects: 150
Study 12424402 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost (0.005%, once daily) for 30 days (monotherapy group)
Number of subjects: 24
Study 12424402 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost (0.005%, once daily) for 180 days (combination treatment group)
Number of subjects: 24
Study 10331150 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy fetuses (normal pregnancies)
Number of subjects: 29
Study 10331150 — intervention group
Group type: COMPARATOR
Intervention: Growth-restricted fetuses (complicated pregnancies)
Number of subjects: 29
Study 8951927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (4, 8, 16 and 20 mg)
Number of subjects: 252
Study 8951927 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 and 20 mg)
Number of subjects: 252
Study 8951927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 8951927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (4 mg)
Number of subjects: 252
Study 8951927 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg)
Number of subjects: 252
Study 8951927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (all doses)
Number of subjects: 252
Study 1657611 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I) at doses of 5, 10, 20, 50 and 100 mg
Number of subjects: 0
Study 1657611 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I) at 10 mg/d for 7 days
Number of subjects: 0
Study 1657611 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I)
Number of subjects: 0
Study 6942835 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g deanol per day
Number of subjects: 33
Study 6942835 — intervention group
Group type: COMPARATOR
Intervention: 1 g deanol per day
Number of subjects: 33
Study 6942835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30827911 — intervention group
Group type: COMPARATOR
Intervention: Sleep Restriction (SR; 5‐h sleep opportunities)
Number of subjects: 36
Study 30827911 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend Recovery (WR; insufficient sleep for 5‐day workweek, then 2 days of weekend recovery)
Number of subjects: 36
Study 30827911 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; 9‐h sleep opportunities)
Number of subjects: 36
Study 30827911 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend Recovery (WR)
Number of subjects: 36
Study 30172435 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care group
Number of subjects: 165
Study 30172435 — intervention group
Group type: COMPARATOR
Intervention: Institutionalized group
Number of subjects: 165
Study 30172435 — intervention group
Group type: COMPARATOR
Intervention: Family care group
Number of subjects: 165
Study 30172435 — intervention group
Group type: COMPARATOR
Intervention: Institutionalized group boys
Number of subjects: 165
Study 30172435 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care group and institutionalized group
Number of subjects: 165
Study 30172435 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of menarche
Number of subjects: 165
Study 27176660 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-awareness intervention manipulation
Number of subjects: 94
Study 27176660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 24898300 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg weekly, uptitrated to 50 mg if necessary)
Number of subjects: 563
Study 24898300 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily prandial insulin lispro
Number of subjects: 563
Study 22723322 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (56.5 μg)
Number of subjects: 578
Study 22723322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 578
Study 20369761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus fentanyl 25 microg and a nitroglycerine patch (Group F-N)
Number of subjects: 120
Study 20369761 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine plus fentanyl 25 microg and a placebo patch (Group F)
Number of subjects: 120
Study 20369761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus saline 0.5 ml and a nitroglycerine patch (Group B-N)
Number of subjects: 120
Study 20369761 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine plus saline 0.5 ml and a placebo patch (Group B)
Number of subjects: 120
Study 17368339 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium perborate + 30% hydrogen peroxide solution (SP + HP)
Number of subjects: 60
Study 17368339 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium perborate + water (SPW)
Number of subjects: 60
Study 17368339 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium perborate + 2% chlorhexidine gel (SP + CHX)
Number of subjects: 60
Study 17368339 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide gel (CP)
Number of subjects: 60
Study 17368339 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide gel + 2% chlorhexidine gel (CP + CHX)
Number of subjects: 60
Study 17368339 — intervention group
Group type: COMPARATOR
Intervention: water (W)
Number of subjects: 60
Study 15746295 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low-frequency electrical stimulation training of the tibialis anterior muscle for 4 weeks
Number of subjects: 0
Study 15746295 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12426215 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (minimum of 25 g animal protein or isolated soy protein/4.2 MJ)
Number of subjects: 42
Study 12426215 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein in individuals with LDL cholesterol > or =4.14 mmol/L
Number of subjects: 42
Study 12426215 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (50 mg/4.2 MJ)
Number of subjects: 42
Study 12426215 — intervention group
Group type: COMPARATOR
Intervention: Animal protein (control group)
Number of subjects: 42
Study 10361533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontailored newsletters
Number of subjects: 710
Study 10361533 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐tailored newsletters
Number of subjects: 710
Study 10361533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletters with tailored goal‐setting information
Number of subjects: 710
Study 10361533 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 710
Study 8534412 — intervention group
Group type: EXPERIMENTAL
Intervention: velnacrine
Number of subjects: 0
Study 8534412 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine
Number of subjects: 0
Study 8534412 — intervention group
Group type: EXPERIMENTAL
Intervention: CI‐979
Number of subjects: 0
Study 2045759 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of vitamin-K-rich vegetables for 7 days (median daily vitamin K intake 1100 micrograms)
Number of subjects: 37
Study 2045759 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of vitamin-K-rich vegetables for 1 day
Number of subjects: 37
Study 2045759 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of vitamin-K-rich vegetables for 2 days
Number of subjects: 37
Study 2045759 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytomenadione supplementation (1000 micrograms daily)
Number of subjects: 37
Study 2045759 — intervention group
Group type: COMPARATOR
Intervention: High intake of vitamin-K-poor vegetables for 6 days
Number of subjects: 37
Study 6992570 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin plus trimethoprim-sulfamethoxazole (C-T/S)
Number of subjects: 126
Study 6992570 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin plus gentamicin (C-G)
Number of subjects: 126
Study 6992570 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results of C-T/S
Number of subjects: 126
Study 6992570 — intervention group
Group type: COMPARATOR
Intervention: Combined results of C-G
Number of subjects: 126
Study 6992570 — intervention group
Group type: EXPERIMENTAL
Intervention: C-T/S
Number of subjects: 126
Study 6992570 — intervention group
Group type: COMPARATOR
Intervention: C-G
Number of subjects: 126
Study 31318923 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression group (n = 113)
Number of subjects: 137
Study 31318923 — intervention group
Group type: COMPARATOR
Intervention: Validation group (n = 24)
Number of subjects: 137
Study 28538515 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue wave stimulus with short-wavelength light (460 nm)
Number of subjects: 28
Study 28538515 — intervention group
Group type: COMPARATOR
Intervention: Green wave stimulus with middle-wavelength light (555 nm)
Number of subjects: 28
Study 28538515 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wavelength light exposure
Number of subjects: 28
Study 26551645 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion/chorion membrane (dHACM) allograft
Number of subjects: 44
Study 26551645 — intervention group
Group type: COMPARATOR
Intervention: Multilayer compression only
Number of subjects: 44
Study 26551645 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall correlation of status at 4 weeks
Number of subjects: 44
Study 23721792 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 197
Study 23721792 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis plus circumcision
Number of subjects: 197
Study 23721792 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis only
Number of subjects: 197
Study 23721792 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncircumcised boys without VUR)
Number of subjects: 197
Study 20800361 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress exposure
Number of subjects: 76
Study 20800361 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 76
Study 18479485 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiparametric maximum likelihood estimate (SPMLE)
Number of subjects: 0
Study 18479485 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum estimated likelihood estimator (MELE)
Number of subjects: 0
Study 17825687 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐OM3 plus simvastatin 40 mg/d
Number of subjects: 254
Study 17825687 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus simvastatin 40 mg/d
Number of subjects: 254
Study 15475724 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour diet recalls
Number of subjects: 395
Study 15475724 — intervention group
Group type: EXPERIMENTAL
Intervention: Food frequency questionnaires (FFQs)
Number of subjects: 395
Study 15475724 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint predictors of 24-hour diet recalls and FFQs
Number of subjects: 395
Study 16210253 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on 16 clinical variables
Number of subjects: 7311
Study 16210253 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model for all-cause death, myocardial infarction, and stroke
Number of subjects: 7311
Study 10482999 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative immunomagnetic ex vivo purging
Number of subjects: 13
Study 8739853 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy
Number of subjects: 110
Study 8739853 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responders to interferon)
Number of subjects: 110
Study 1654364 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of acyclovir five times daily for 10 days
Number of subjects: 120
Study 1654364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 1654364 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of acyclovir
Number of subjects: 120
Study 6886352 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine plus meperidine (Group 2)
Number of subjects: 45
Study 6886352 — intervention group
Group type: COMPARATOR
Intervention: Meperidine alone (Group 1)
Number of subjects: 45
Study 6886352 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy (after premedication)
Number of subjects: 45
Study 31965238 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 27
Study 30224275 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-oriented silence
Number of subjects: 217
Study 30224275 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-oriented speech
Number of subjects: 217
Study 30224275 — intervention group
Group type: COMPARATOR
Intervention: Standard communication
Number of subjects: 217
Study 23494593 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drainage for 5 days or drain removal when less than 50 mL/24 h
Number of subjects: 214
Study 23494593 — intervention group
Group type: COMPARATOR
Intervention: Conventional drain removal
Number of subjects: 214
Study 24710800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 108
Study 24710800 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopically Assisted Vaginal Hysterectomy (LAVH)
Number of subjects: 108
Study 24710800 — intervention group
Group type: COMPARATOR
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 108
Study 22264134 — intervention group
Group type: EXPERIMENTAL
Intervention: FM-MP (Face Mask with Miniplates)
Number of subjects: 20
Study 22264134 — intervention group
Group type: EXPERIMENTAL
Intervention: FM-RME (Face Mask with Rapid Maxillary Expansion)
Number of subjects: 20
Study 19182619 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential negative-pressure wound therapy at -400 mmHg
Number of subjects: 32
Study 19182619 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential negative-pressure wound therapy at -125 mmHg
Number of subjects: 32
Study 19182619 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncircumferential negative-pressure wound therapy at -400 mmHg
Number of subjects: 32
Study 19182619 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncircumferential negative-pressure wound therapy at -125 mmHg
Number of subjects: 32
Study 19182619 — intervention group
Group type: COMPARATOR
Intervention: Circumferential negative-pressure wound therapy at -400 mmHg vs -125 mmHg
Number of subjects: 32
Study 19182619 — intervention group
Group type: COMPARATOR
Intervention: Noncircumferential negative-pressure wound therapy at -400 mmHg vs -125 mmHg
Number of subjects: 32
Study 17402668 — intervention group
Group type: COMPARATOR
Intervention: Monocular switch procedure
Number of subjects: 0
Study 17402668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismatic displacement
Number of subjects: 0
Study 15339325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter repair plus biofeedback
Number of subjects: 38
Study 15339325 — intervention group
Group type: COMPARATOR
Intervention: Sphincter repair
Number of subjects: 38
Study 11524060 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted cardioverter-defibrillator therapy
Number of subjects: 0
Study 9519950 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (twice weekly for 24 weeks)
Number of subjects: 750
Study 9519950 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin and pyrazinamide (twice weekly for 8 weeks)
Number of subjects: 750
Study 9519950 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin and pyrazinamide
Number of subjects: 750
Study 9519950 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 750
Study 9519950 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4 percentages <20
Number of subjects: 750
Study 9519950 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mortality
Number of subjects: 750
Study 8026409 — intervention group
Group type: EXPERIMENTAL
Intervention: High Vagus Nerve Stimulation (VNS)
Number of subjects: 67
Study 8026409 — intervention group
Group type: COMPARATOR
Intervention: Low Vagus Nerve Stimulation (VNS)
Number of subjects: 67
Study 29247985 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow movement resistance training using body weight (SRT-BW) for 12 weeks
Number of subjects: 88
Study 29247985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study 28285771 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 142
Study 28285771 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 142
Study 25499543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (50,000 IU)
Number of subjects: 31999
Study 25499543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31999
Study 24163529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid microinjections
Number of subjects: 60
Study 24163529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid with microneedling
Number of subjects: 60
Study 21367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality pharmacotherapy
Number of subjects: 1004
Study 21367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate dose of antianxiety medication
Number of subjects: 1004
Study 21367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling with at least 1 element of CBT
Number of subjects: 1004
Study 21367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling with strong CBT focus (3+ elements)
Number of subjects: 1004
Study 21367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality pharmacotherapy or psychotherapy
Number of subjects: 1004
Study 21367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both quality pharmacotherapy and psychotherapy
Number of subjects: 1004
Study 21367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with mental health care
Number of subjects: 1004
Study 21367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality psychotherapy
Number of subjects: 1004
Study 21367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of CBT elements delivered
Number of subjects: 1004
Study 18384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant drugs (2-4 types) and other psychotropic drugs
Number of subjects: 289
Study 18384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple antidepressants, tricyclic antidepressants, hypnosedatives, lithium, and/or antipsychotics
Number of subjects: 289
Study 17065538 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscle training for 2-4 weeks
Number of subjects: 26
Study 17065538 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscle training
Number of subjects: 26
Study 17065538 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 26
Study 17065538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (preoperative inspiratory muscle training)
Number of subjects: 26
Study 12934220 — intervention group
Group type: EXPERIMENTAL
Intervention: Histomorphologic analysis of the prosthetic bone bed
Number of subjects: 23
Study 12934220 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 23
Study 12934220 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum total point motion (MTPM) analysis
Number of subjects: 23
Study 12934220 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of the bone bed
Number of subjects: 23
Study 12934220 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bone quality evaluation
Number of subjects: 23
Study 11073508 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 66000
Study 11073508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66000
Study 11073508 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (doses below 163 mg/day)
Number of subjects: 66000
Study 11073508 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified release formulations of aspirin
Number of subjects: 66000
Study 9339405 — intervention group
Group type: COMPARATOR
Intervention: 20% mannitol (M)
Number of subjects: 50
Study 9339405 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline solution (HS)
Number of subjects: 50
Study 9339405 — intervention group
Group type: COMPARATOR
Intervention: Both M and HS
Number of subjects: 50
Study 8439639 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole daily
Number of subjects: 0
Study 8439639 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine b.d.s. plus 10 mg metoclopramide q.d.s.
Number of subjects: 0
Study 2875321 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS‐201‐995 0.4 microgram/kg
Number of subjects: 8
Study 2875321 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS‐201‐995 up to 1.6 micrograms/kg
Number of subjects: 8
Study 2875321 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS‐201‐995 0.8 microgram/kg
Number of subjects: 8
Study 2875321 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS‐201‐995
Number of subjects: 8
Study 27863165 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth screening, brief intervention and referral to treatment (SBIRT)
Number of subjects: 226
Study 27863165 — intervention group
Group type: COMPARATOR
Intervention: eHealth control
Number of subjects: 226
Study 25943761 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care with smoking cessation services
Number of subjects: 943
Study 25943761 — intervention group
Group type: COMPARATOR
Intervention: Standard care (referral to a smoking cessation clinic)
Number of subjects: 943
Study 24523025 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation training
Number of subjects: 55
Study 24523025 — intervention group
Group type: COMPARATOR
Intervention: Dietary and physical activity advice
Number of subjects: 55
Study 22704099 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655